Its role Owner
Novo Nordisk is a global healthcare company headquartered in Bagsværd, Denmark. Founded in 1923, it researches, develops, manufactures, and markets medicines for serious chronic diseases. The company is listed on Nasdaq Copenhagen, with American Depositary Receipts traded in the U.S.
Core areas include diabetes and obesity, as well as rare endocrine and blood disorders. Its portfolio spans human and analogue insulins, GLP-1–based therapies, and other peptide and protein biologics. Novo Nordisk operates extensive bioprocessing, active pharmaceutical ingredient production, formulation, and fill–finish facilities worldwide, and collaborates with academic and industry partners on emerging modalities such as cell therapy.
Also known as Novo and NVO.
chemXplore tracks 5 projects involving Novo Nordisk, of which 3 are active.
Besides these 3, the record holds 2 completed projects.
Closest to start-up first.
The 2 that are completed, on hold or cancelled are in the record. See all 5 in chemXplore →
The dates themselves, per project, are for subscribers.
FDA review remains ongoing; extension caused by facility remediation, not clinical deficiencies. Novo still targets a US launch in H1 2027 and says 2026 outlook is unaffected.
MRI‑PDFF subanalysis (n=55) found mean liver fat fell from 8.8% to 3.1% at week 72; 88.5% with baseline liver fat >5% reached <5%.
Ro telehealth real-world data: mean 4.1% weight loss at three months; 40.7% reached ≥5% loss; obesity (BMI≥30) prevalence fell 21.6 percentage points; N=194.
fMRI shows reduced ‘food noise’ and cravings; trials report major weight loss, reductions in abdominal/liver/pancreas fat and preliminary bone‑marker reassurance.
Phase‑1 ready oral GLP‑1/GIP dual agonist with up to $2.6bn deal value including $300m upfront; development and commercial rights exclude Greater China.
Real-world claims analysis found escalating from semaglutide 1 mg to 2 mg tied to a 6% lower risk of major adverse cardiovascular events than switching to tirzepatide.
CagriSema 1.0/1.0 delivered greater weight loss than tirzepatide 5 mg and 21% vs 2% vs placebo in obesity trial; HbA1c reduction was non‑inferior. FDA decision expected Q4 2026.
Once-weekly somapacitan (Sogroya) receives CHMP positive opinion for children with idiopathic short stature; European Commission decision expected later this year.
